Pharmaceutical

The privileged status of orphan medicines in Germany

In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question this market’s desirability for orphan drug developers.

Apr 27, 2024 - 00:00
The privileged status of orphan medicines in Germany
In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question this market’s desirability for orphan drug developers.
Read the original article

Tags:

Previous Article

Pioneer Institute study finds IRA discourages non-opioid drug innovation

Next Article

Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price t...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer

Nestlé divests peanut allergy treatment Palforzia to St...

Sep 5, 2023

STAT+: Amazon strikes partnership with 3M to advance conversational AI in medicine

STAT+: Amazon strikes partnership with 3M to advance co...

Apr 19, 2023

Opinion: We finally have new Alzheimer’s drugs. How do we decide who gets them?

Opinion: We finally have new Alzheimer’s drugs. How do ...

Jul 8, 2023